Press releases

Pharmaleads Reports Positive Ocular Pain Results with PL265, a Novel Dual Enkephalinase Inhibitor (DENKI), at the ARVO 2017 Annual Meeting

Pharmacology research conducted in conjunction with The Vision Institute, Paris  Paris, France, 12th May 2017 – Pharmaleads, an emerging pharmaceutical company developing innovative products for the management of acute and chronic severe pain, today announced positive efficacy and safety results of PL265, a novel Dual ENKephalinase Inhibitor (DENKI),  in a preclinical study for ocular pain. […] Read full post »

Pharmaleads to Present PL265 for Ocular Pain Results at the ARVO 2017 Annual Meeting in Baltimore

Paris, France, 5th May 2017 – Pharmaleads, an emerging pharmaceutical company developing innovative products for the management of acute and chronic severe pain, today announced that a poster presentation on its Dual ENKephalinase Inhibitor (DENKI) PL265 has been accepted for presentation at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting […] Read full post »

Pharmaleads announces the opening of french sites in its international Phase IIa clinical study of PL37

ANSM (French National Agency for Medicines and Health Products Safety) authorizes the extension of the clinical trial for pain in diabetic neuropathy   Paris, September 28, 2015 – Pharmaleads, the biotech company developing its proprietary Dual Enkephalinase Inhibitors (DENKIs) for the treatment of severe pain, announces today the opening of the first French investigative sites in […] Read full post »

Older posts

Page 1 of 212
Discover our publications
Press & media coverage
Contact & find us

Pharmaleads SA
11, rue Watt
75013 Paris

Tel: +33 (0)1 44 06 70 00
Fax: +33 (0)1 44 06 60 99
info@pharmaleads.com

Get the access map